# Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma

> **NCT04655157** · PHASE1,PHASE2 · TERMINATED · sponsor: **Jason J. Luke, MD** · enrollment: 2 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** encorafenib
- **DRUG:** nivolumab
- **DRUG:** ipilimumab
- **DRUG:** binimetinib

## Key facts

- **NCT ID:** NCT04655157
- **Lead sponsor:** Jason J. Luke, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-05-28
- **Primary completion:** 2022-08-03
- **Final completion:** 2022-09-20
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Study terminated due to slow enrollment
- **Last updated:** 2024-05-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04655157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04655157, "Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04655157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*